What Is eTMF in Clinical Trials? A Complete Guide

When Documentation Became Infrastructure

The EU Clinical Trials Regulation (No 536/2014) entered into application on January 31, 2022, when the Clinical Trials Information System (CTIS) launched ^[16]. From January 31, 2023, CTIS became the sole submission channel for all new clinical trial applications across EU and EEA member states, ending the transition period during which sponsors could still apply under the older Clinical Trials Directive ^[16]. Sponsors who had submitted new applications under the older Clinical Trials Directive could no longer do so after that date, and those running ongoing trials had until January 31, 2025 to migrate into CTIS ^[16]. For those who had not yet built a filing taxonomy capable of handling regional-level documentation, the transition exposed a structural gap.

The requirement to maintain essential trial records originates in the original ICH E6 guideline for Good Clinical Practice, published in 1996 ^[2]. The current ICH E6(R3) guideline, finalized by the ICH Assembly on January 6, 2025 ^[1], sets expectations for what belongs in that record and who is responsible for maintaining it, while pointing to applicable regulatory requirements such as EU and UK law for specific retention periods. Understanding the eTMF means understanding the regulatory logic behind it, not just the software platform that houses it.

Why eTMF Has Become a Strategic Priority

A 2025 market research analysis by MarketsandMarkets estimated the global eTMF systems market at USD 1.36 billion in 2025, projecting growth to USD 2.49 billion by 2030 at a CAGR of 12.8% ^[14]. That trajectory reflects a structural shift in how sponsors, CROs, and sites approach trial documentation. Growing regulatory requirements from agencies including the FDA, EMA, ICH, and MHRA, combined with the operational demands of decentralized and hybrid trial designs, have made a well-functioning eTMF a practical necessity for any organization running complex, multi-site studies.

The adoption data confirms the direction of travel. A CDISC survey of sponsors, CROs, vendors, sites, and consultants found that implementation of the TMF Reference Model, the industry's standard taxonomy for organizing TMF content, rose from 52% to 92% among pharmaceutical and life sciences organizations ^[11]. Over the same period, the proportion of organizations maintaining fully electronic Trial Master Files and Investigator Site Files climbed from 8% to 65% ^[11]. Paper TMFs remain technically permissible in most jurisdictions, but they are functionally impractical for any trial running across multiple sites, countries, or regulatory regions.

Paper TMF and eTMF: The Same Regulatory Requirement, Different Infrastructure

The regulatory obligation is for a Trial Master File, not specifically for an electronic one. According to FDA and international GCP guidelines, TMFs are required for every study, but are not required to be electronic ^[10]. The eTMF is a technology choice for satisfying that requirement electronically. What does change with the electronic format are the technical obligations: an eTMF system must comply with applicable computer system requirements, including 21 CFR Part 11 in the US and the EMA Guideline on Computerised Systems and Electronic Data in Clinical Trials, effective September 2023, for EU-regulated studies ^[4],[25]. Regulatory agencies do not require eTMF systems to follow any particular software product, but they do require that whatever system is used can be validated as fit for its intended purpose.

What Makes a Document "Essential" Under ICH GCP

Not every document produced during a clinical trial belongs in the TMF. The designation "essential" carries a specific regulatory meaning. According to ICH E6(R3) Appendix C, essential records are those that individually and collectively permit evaluation of the conduct of a trial in relation to GCP compliance, applicable regulatory requirements, and the reliability of the data produced ^[1],[6]. They also serve as the evidentiary foundation for investigator and sponsor oversight, including monitoring activities, throughout the trial lifecycle.

Essential documents change across the trial timeline. Before a trial begins, core records include the approved protocol and any amendments, the Investigator's Brochure (IB), ethics committee and regulatory authority approvals, financial disclosure forms, signed investigator agreements, delegation of authority logs, and documented evidence of investigator qualifications. During conduct, the essential record set expands to include monitoring visit reports, correspondence with regulatory authorities, serious adverse event reports, updates to the IB, and documentation of laboratory certifications. At trial closeout, the TMF receives the final clinical study report, confirmation of investigational product accountability, and records confirming site notification of trial completion.

ICH E6(R3) introduced a material shift in how sponsors approach the scope of the TMF. The revised guideline explicitly adopts a risk-proportionate approach: the nature and extent of records generated and maintained should depend on the trial design, its conduct, and the importance and relevance of each record to that specific trial ^[3]. Standard operating procedures, system validation records, and master service agreements that apply across multiple studies may now be retained outside the TMF itself, rather than duplicated in each study file ^[3]. This is a practical departure from the more exhaustive approach in E6(R2), and it gives sponsors documented flexibility, provided they can justify their filing decisions to an inspector.

The Regulatory Frameworks That Govern eTMF Systems

FDA: 21 CFR Part 11 and 21 CFR Part 312

In the United States, any eTMF system used to store regulated clinical trial documents must comply with FDA 21 CFR Part 11, which sets requirements for electronic records and electronic signatures ^[4]. A compliant system must support time-stamped audit trails recording document creation, modification, and deletion; access controls limiting viewing, editing, and approval rights to authorized users; and mechanisms capable of detecting unauthorized alterations to records. For investigational new drug applications, 21 CFR Part 312 defines sponsor and investigator recordkeeping and retention obligations, including which categories of records must be maintained and for how long ^[22]. These obligations directly inform the scope and content of the sponsor's TMF, though Part 312 itself does not prescribe a specific TMF taxonomy.

ICH E6(R3): Finalized January 2025

ICH E6(R3) reached Step 4 final endorsement on January 6, 2025, after a Step 2 draft circulated for public consultation beginning in May 2023 ^[1]. ICH E6(R3) principles have been incorporated into the amended UK Clinical Trials Regulations, which came into force on April 28, 2026 ^[8]. The guidance made several TMF-specific changes of operational significance. All essential records must be identifiable and version-controlled. Protections for blinding and participant privacy must be considered when sharing records across stakeholders. ICH E6(R3) also references the EU's 25-year archive retention period, and notes that investigator retention obligations apply for the period required under applicable regulatory requirements or until the sponsor confirms records are no longer needed, whichever is longer ^[3].

EU CTR and Mandatory 25-Year Archiving

Under Article 58 of EU Regulation No 536/2014, the sponsor and the investigator must archive the content of the clinical trial master file for at least 25 years after the end of the trial, in a way that ensures it remains readily available and accessible to competent authorities upon request ^[5]. That provision came into effect when the EU CTR became fully operational. The CTR also requires that any alteration to the content of the TMF be traceable ^[5].

CTIS became the single entry point for all new EU clinical trial applications on January 31, 2023 ^[16]. From January 31, 2025, any trial previously authorized under the Clinical Trials Directive that remained active was required to have migrated its information into CTIS ^[16]. The CTR consolidated what had been country-by-country regulatory submissions into a single application. Documentation previously filed only at the national level now includes an EU/EEA-level CTIS submission layer, and TMF taxonomies need to reflect that structure ^[18].

MHRA and UK Clinical Trials Regulations

The MHRA requires that any eTMF system be appropriately validated before use, with documented evidence that it is fit for its intended purpose ^[7]. The amended UK Clinical Trials Regulations, which came into force on April 28, 2026, introduced a 25-year minimum TMF retention period, up from the previous 5 years ^[8]. There is an important transitional provision: trials where the application was submitted before April 28, 2026 retain the 5-year TMF obligation under old regulation 31A(7), while trials submitted on or after that date must comply with the 25-year requirement ^[9]. Sponsors running trials that span both regimes need to distinguish which standard applies to which study when designing their archiving infrastructure.

The DIA TMF Reference Model: The Industry's Standard Taxonomy

The TMF Reference Model was created in 2010 through work initiated under the Document and Records Management Community of the Drug Information Association (DIA), based on regulatory feedback from across the industry ^[13]. Governance of the model transferred to CDISC in June 2022 ^[12]. Its purpose is direct: establish a single, unified interpretation of TMF content, grounded in ICH GCP and other applicable regulations, that any organization can adapt to its own processes, whether using paper or electronic filing systems ^[13].

The Reference Model organizes TMF content through a hierarchical structure of zones, sections, and individual artifacts, with standardized naming conventions and minimum metadata definitions for eTMF systems ^[13],[15]. The DIA's published structure covers areas including trial management, central trial documents, regulatory submissions, IRB/IEC and other approvals, site management, investigational product and trial supplies, and additional operational areas ^[15]. It is not a regulatory requirement. It is industry guidance, and inspectors do not require organizations to follow it exactly, but its widespread adoption means that TMF structures diverging substantially from it tend to require justification during inspections.

CDISC surveys show that adoption has reached 92% of pharmaceutical and life sciences organizations, and 74% of those organizations have customized the model to meet their specific trial portfolio needs ^[11]. CDISC published the V4 project page in January 2025 ^[12], following the roadmap launch in September 2024 ^[11]. The project is in active development, with zone committees, an Investigator Site File sub-team, and metadata working groups contributing to the next major version ^[26].

What Goes Wrong: TMF Deficiencies in Regulatory Inspections

The MHRA publishes annual GCP Inspection Metrics Reports documenting findings across commercial sponsors, CROs, non-commercial organizations, and investigator sites ^[19]. In the MHRA GCP Inspections Metrics Report covering April 2018 to March 2019, Record Keeping and Essential Documents was the single most frequently cited area for commercial sponsor inspections, accounting for approximately 18% of all sponsor inspection observations ^[20]. TMF-related findings appeared across the full range of inspection types, with 33 individual observations related specifically to the eTMF documented in that report alone ^[20].

An analysis of MHRA inspection findings from 2016 to 2023, obtained through a Freedom of Information request and published by Arkivum, identified 75 findings across 39 organizations ^[21]. Seven of those nine organizations reviewed in one FOI batch had gaps in electronic archiving processes. Four lacked documented retention policies, and three had unclear TMF scope, with essential records distributed across multiple systems and service providers without a single, controlled view ^[21].

The categories of findings are consistent across MHRA, FDA, and EMA inspections. Missing or incomplete essential documents appear most frequently: absent signed CVs for investigators, unsigned delegation of authority logs, missing financial disclosure forms, and incomplete ethics committee approval records. These documents must be in place before the trial begins, and their absence at inspection suggests that required safeguards may not have been active during conduct.

Poor version control creates a separate category of risk. When multiple versions of a protocol, an informed consent form, or a monitoring report circulate without clear traceability showing which version governed trial conduct at which moment, the TMF cannot fulfill its core function: it cannot allow reconstruction of what actually happened during the trial. Inadequate oversight of CRO-managed TMF components is also a persistent finding, particularly at study closeout when responsibility for the complete TMF transfers back to the sponsor and document status is audited systematically for the first time.

Each of these findings shares a structural cause: a gap between when something occurred in the trial and when it was documented, or between what was required and what was filed. An eTMF system addresses the housing and access problem. It does not automatically close the process and oversight gap.

AI and Automation in eTMF: What Is Real, What Requires Scrutiny

Many eTMF vendors now offer machine learning capabilities for document management tasks. In 2024, these technologies were applied primarily to document classification, metadata tagging, and redaction of personal data from documents designated for public disclosure ^[24]. The practical case for automation centers on volume: a large Phase III trial may generate tens of thousands of documents across dozens of sites, multiple CROs, and several regulatory jurisdictions. Manual classification and filing at that scale is slow and error-prone.

One vendor reported a 60% reduction in time per document for classification tasks using an AI-based filing agent ^[23]. That figure reflects a single platform's internal benchmarks in specific trial environments and should be read as illustrative rather than an industry-wide measure. The broader direction, however, is consistent: automated classification, when properly validated, can reduce the lag between document generation and compliant filing in the eTMF, directly addressing the timeliness failures that inspectors cite regularly.

Several cautions apply. Validation requirements under 21 CFR Part 11 and GCP apply to AI-assisted eTMF systems in the same way they apply to any computer system used in a regulated clinical trial. An automated classification model that systematically misfiles documents could introduce errors at scale rather than reducing them. Current implementations typically address this through confidence thresholds: documents classified below a defined level of certainty are flagged for human review before filing, and every automated action is logged in the audit trail ^[23]. That design preserves traceability and maintains the human oversight layer that regulators expect.

Automation does not substitute for a well-designed TMF plan and trained staff. The TMF Reference Model provides the structural taxonomy, but the SOPs governing what must be filed, within what timeframe, and by which party remain the sponsor's responsibility regardless of how much automation the system provides. The question to ask about any AI-enabled eTMF feature is not whether it works in a demo environment, but whether it has been validated, documented, and subject to human oversight in a way that would withstand an inspection.

How Kitsa Fits Into the eTMF Workflow

The documents that populate a TMF do not exist in isolation. A protocol amendment triggers updates to the Investigator's Brochure, the Informed Consent Form, and monitoring procedures. Each of those updates must be version-controlled, cross-consistent, and filed with correct metadata. KScribe, Kitsa's regulatory document generation product, is designed to produce regulatory documents, including protocols, IBs, ICFs, and clinical study reports, with the cross-document alignment and version traceability that eTMF management requires. Generating these documents with built-in consistency can help reduce the version-control risk that remains among the most frequently cited TMF inspection findings.

Key Takeaways

• •The Trial Master File is a regulatory requirement under ICH GCP for every clinical trial. Its contents must allow inspectors to fully reconstruct the conduct of the trial and evaluate GCP compliance. The TMF does not have to be electronic, but the eTMF has become the widely adopted practice for any multi-site, multi-country trial.
• •ICH E6(R3), finalized on January 6, 2025, introduced a risk-proportionate approach to TMF content, giving sponsors documented flexibility to determine what is essential based on trial design, while requiring that all retained records be identifiable, version-controlled, and accessible for the full retention period [1][3].
• •Under EU Regulation No 536/2014, Article 58, sponsors and investigators must archive the clinical trial master file for at least 25 years after the trial ends [5]. In the UK, the 25-year requirement applies to trials with applications submitted on or after April 28, 2026; trials submitted before that date retain a 5-year TMF obligation under transitional provisions [9].
• •The DIA TMF Reference Model, now under CDISC governance since June 2022 [12], has been adopted by 92% of pharmaceutical and life sciences organizations [11]. Version 4 is under active development following the CDISC roadmap unveiled in September 2024 [11][12]. The model is industry guidance, not regulation, but diverging from it substantially requires justification.
• •The most consistent TMF inspection findings include missing essential documents, inadequate version control, TMF scope gaps that leave records outside the controlled file, and insufficient sponsor oversight of CRO-managed TMF components [20][21].
• •Many eTMF vendors now offer AI-based document classification, with vendor-reported benefits including faster filing and reduced metadata errors. All automated systems in regulated environments require validation under 21 CFR Part 11 and GCP, and human review thresholds must be defined and documented [23].
• •The EU CTR transition introduced an EU/EEA-level CTIS submission layer for all new clinical trial applications from January 31, 2023 [16], and all ongoing Directive trials were required to migrate into CTIS by January 31, 2025 [16]. TMF taxonomies must reflect this additional documentation layer [18].

Frequently Asked Questions

References

You Might Also Like